Coronavirus information from UCLA and UCLA Health.


The Next Generation Incubator

Qwixel Therapeutics addresses the need to develop therapeutics to treat multiple myeloma (MM), a B cell cancer disease that is not curable.

Qwixel Therapeutics is a pre-clinical company focused on utilizing IFNs as potent anti-cancer agents. In order to treat cancer effectively, high concentrations of IFN at the tumor must be obtained. Qwixel's goal is to concentrate IFN at the tumor site by fusing it to antibodies that recognize CD138, a protein expressed on the surface of myeloma cells. Qwixel's advantages include the potential to cure disease, improve patient quality of life, and increase life expectancy. Qwixel Therapeutics merged with Nammi Therapeutics in 2021.

Graduated: 2021
Location: Los Angeles, CA